ICU Medical 3Q 2026: Revenue $560.44M, EPS $1.07 — 10-Q Summary
ICU Medical reported 3Q 2026 revenue of $560.44M, up 4.4% YoY, with net income of $26.85M, reversing a prior-year loss. Growth in Consumables and Infusion Systems offset a decline in Vital Care. Gross margin improved to 41.9% due to tariff refunds and price increases, according to the company.
How this was made
The 30-second read
Why it matters
The earnings surprise could trigger short‑term buying pressure, especially in after‑hours trading.
Market read
First‑report earnings data for a small‑cap medical‑device firm; may influence sector sentiment.
What to watch
Lower Vital Care revenue and the $4M impairment could pressure future margins.
Background
ICU Medical filed its 10‑Q for Q3 2026, showing a turnaround to profitability.
Ticker impact
Q3 2026 revenue $560.44M (+4.4% YoY) and EPS $1.07, turning a loss into $26.85M net income.
potential upside as market prices in earnings beat and higher gross margin.
The company posted a profit after a loss year‑over‑year, with revenue growth in key segments and improved margins.
Market effects
Medical‑device sector may see modest uplift from ICU Medical's earnings beat.
U.S. healthcare equities could benefit in the near term.
Limited to U.S. and global medical‑device investors.
Counterpoint
Profitability may be temporary given the impairment charge and weakness in Vital Care sales.
Key entities
- companyICU Medical Inc.
Medical‑device manufacturer listed on Nasdaq (ICUI).
